Utama › Gangguan Depresi Major › Arkansas
Kajian klinikal Gangguan Depresi Major di Arkansas
15 kajian untuk Gangguan Depresi Major sedang mencari peserta di lokasi di Arkansas.
Bandar di Arkansas
Teks kajian rasmi (Bahasa Inggeris)
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06559306Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Little Rock
Mengambil pesertaFasa 3
Umur 18 hingga 65 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Bryant
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT07105111A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Pillar Clinical Research, Bentonville
- SanRo Clinical Research Group, Bryant
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Little Rock
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07610473A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Bentonville
- Draig Clinical Site, Little Rock
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT07300969NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Preferred Research Partners, Inc., Little Rock
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT07592689A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Woodland International Research Group, Little Rock
- Woodland Research Northwest, Rogers
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06775379Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
- Neurocrine Clinical Site, Little Rock
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06966401A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Preferred Research Partners /ID# 279206, Little Rock
- Woodland International Research Group /ID# 277605, Little Rock
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 15 Jun 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Pillar Clinical Research, LLC, Little Rock
- Preferred Research Partners, Inc., Little Rock
- Woodland Research Northwest, Rogers
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 11 Mei 2026 · NCT06524830Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Little Rock
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Okt 2025 · NCT06786624Study of ALTO-300 in MDD
- Site 193, Rogers
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Jul 2025 · NCT05922878Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.